Yue Wu Biography and Net Worth

Director of Scilex


Yue Alexander Wu is co-founder and CEO of Cothera Bioscience, Inc., a translation medicine and precision therapeutics company.

He was previously President, Chief Executive Officer and Chief Strategy Officer of Crown Bioscience International, a leading global drug discovery and development solutions company, which he co-founded in 2006, until 2017.

From 2004 to 2006, Dr. Wu was Chief Business Officer of Starvax International Inc. in Beijing, China, a biotechnology company focusing on oncology and infectious diseases. From 2001 to 2004, Dr. Wu was a banker with Burrill & Company where he was head of Asian Activities.

Dr. Wu has served as a director of CASI Pharmaceuticals, Inc. (Nasdaq: CASI) since June 2013 and Sorrento Therapeutics, Inc. since August 2016. Dr. Wu received his Ph.D. in Molecular Cell Biology and his MBA from University of California at Berkeley.

He earned an M.S. in Biochemistry from University of Illinois, Urbana-Champaign and his B.S. in Biochemistry from Fudan University in Shanghai, China.

What is Yue Alexander Wu's net worth?

The estimated net worth of Yue Alexander Wu is at least $3,884.16 as of October 17th, 2024. Wu owns 714 shares of Scilex stock worth more than $3,884 as of May 4th. This net worth approximation does not reflect any other assets that Wu may own. Learn More about Yue Alexander Wu's net worth.

How do I contact Yue Alexander Wu?

The corporate mailing address for Wu and other Scilex executives is 1 Harbourfront Avenue #16-06 Keppel Bay Tower, Singapore U0, 098632. Scilex can also be reached via phone at 650-516-4310 and via email at investorrelations@scilexholding.com. Learn More on Yue Alexander Wu's contact information.

Has Yue Alexander Wu been buying or selling shares of Scilex?

Yue Alexander Wu has not been actively trading shares of Scilex during the last ninety days. Most recently, on Thursday, October 17th, Yue Alexander Wu bought 571 shares of Scilex stock. The stock was acquired at an average cost of $33.25 per share, with a total value of $18,985.75. Following the completion of the transaction, the director now directly owns 714 shares of the company's stock, valued at $23,740.50. Learn More on Yue Alexander Wu's trading history.

Are insiders buying or selling shares of Scilex?

In the last year, Scilex insiders bought shares 8 times. They purchased a total of 7,658 shares worth more than $230,445.95. The most recent insider tranaction occured on December, 18th when insider Jaisim Shah bought 857 shares worth more than $13,797.70. Insiders at Scilex own 7.7% of the company. Learn More about insider trades at Scilex.

Information on this page was last updated on 12/18/2024.

Yue Alexander Wu Insider Trading History at Scilex

See Full Table

Yue Alexander Wu Buying and Selling Activity at Scilex

This chart shows Yue Alexander Wu's buying and selling at Scilex by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$10k$0$10kTotal Insider BuyingTotal Insider Selling

Scilex Company Overview

Scilex logo
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.
Read More

Today's Range

Now: $5.44
Low: $5.10
High: $5.58

50 Day Range

MA: $8.29
Low: $3.99
High: $12.25

2 Week Range

Now: $5.44
Low: $3.60
High: $80.50

Volume

143,487 shs

Average Volume

52,455 shs

Market Capitalization

$37.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04